MedTrace Logo

Contingency Management Using Smartphone App in Patients With SUD

NCT04162132 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 108

Last updated 2019-11-20

No results posted yet for this study

Summary

The purpose of this research study is to test the acceptance and efficacy of a smartphone app (DynamiCare Rewards) for patients with substance use disorder (SUD) who are in active treatment and recovery at BrightView.

Conditions

Interventions

DEVICE

Smartphone app

Study procedures related to the DynamiCare Rewards intervention were conducted via smartphone. Research visits included collection of urine samples and medical exams. Participants assigned to the DynamiCare Rewards group received: 1) the app on their smartphone, 2) drug testing devices when indicated (pocket-sized breathalyzer), and a reloadable debit card for receiving the financial incentives (the PEX debit card). Global Positioning System (GPS) tracking was used to track whether patients had attended their scheduled appointments but was not used at any other times. All information was uploaded from the app onto the DynamiCare Analytics website, which treatment providers could view. The information reported was: attendance status of appointments, the status of all alcohol and drug testing, and incentives earned. Each patient's intervention period (period of time when they used the app) lasted four months from the date of their enrollment.

Sponsors & Collaborators

  • DynamiCare Health

    collaborator INDUSTRY

  • BrightView LLC

    lead INDUSTRY

Principal Investigators

  • Shawn Ryan, MD, MBA · President & CMO

  • Samin Rezania, PhD · Director of Clinical Research

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-01-25
Primary Completion
2019-07-29
Completion
2019-07-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04162132 on ClinicalTrials.gov